🇺🇸

US SEC Filing Intelligence

· daily

USA Insider Trading Pulse — September 24, 2026

The September 24, 2026, insider trading pulse reveals a day dominated by high-value, pre-planned insider selling at the C-suite level, particularly in the technology and healthcare sectors. Notable disposals include SpaceX's President Gwynne Shotwell ($23.4M), Tempus AI's CEO Eric Lefkofsky ($6.1M), and Royalty Pharma's EVP Christopher Hite ($5.6M), all executed under Rule 10b5-1 plans, suggesting portfolio diversification rather than panic. However, a stark contrast emerges with significant insider buying from major institutional holders: Nippon Life Insurance increased its stake in Corebridge Financial by $10.2M, and a director at Advanced Flower Capital added $92.6K, signaling strong conviction in these financial and cannabis-related assets. The data shows a bifurcated market where insiders at high-growth, volatile names are taking profits, while deep-value and financial sector insiders are deploying capital. A cluster of routine director stock awards at UnitedHealth Group (12 filings) and Precision Optics (3 filings) indicates standard compensation practices, providing no directional signal. The most actionable intelligence lies in the divergence between the large-scale selling at SpaceX and Tempus AI and the bullish accumulation in Corebridge Financial and Advanced Flower Capital.

49 high priority 1 medium 50 total filings
· daily

US Merger & Acquisition SEC Filings — September 24, 2026

The US SPAC market is experiencing a surge in activity with three major capital raises and one key merger amendment this week. Black Hawk Acquisition Corp secured a complex $200M+ financing package for its Vesicor Therapeutics combination, though at a high cost with a 15% discount on prepaid advances. Haymaker Acquisition Corp V completed a $295.5M IPO and private placement, signaling strong investor appetite for new SPACs. Live Oak Acquisition Corp VI priced a $200M IPO, adding to the $495.5M in fresh SPAC capital raised this period. UY Scuti Acquisition Corp amended its merger with Isdera Group, setting a $920M valuation and adjusting conversion terms. Columbus Acquisition Corp and ARC Group Securities Acquisition I filed procedural updates with no financial impact. The dominant theme is the continued flow of SPAC capital formation and deal financing, with a notable shift toward costly but necessary financing structures to close pending business combinations.

6 high priority 6 total filings
· monthly

US Pre-Market SEC Filings Roundup — September 24, 2026

The overnight filing period from September 23-24, 2026, presents a complex picture for the US market, dominated by significant corporate actions and mixed financial results. A key theme is aggressive capital management, with major buyback announcements from Mizuho Financial Group and a substantial tender offer from Utah Medical Products, alongside a large secondary offering from InnovAge Holdings. The period also features transformative M&A, including a merger between Afya and Yduqs in Brazilian education and a SPAC combination for Elroy Air, alongside a major debt refinancing by AMC Entertainment. Financially, the picture is bifurcated: AtlasClear Holdings reported explosive revenue growth but deteriorating profitability, while Key Tronic Corp posted a dramatic loss. Insider activity was mixed, with notable purchases in DeFi Development Corp and CapsoVision, countered by significant sales at GigaCloud Technology and Bullish. The most actionable signals point to opportunities in capital return stories and risks in companies with widening losses and shareholder dilution.

28 high priority 22 medium 50 total filings
· daily

Biotech Small-Cap Approvals — September 23, 2026

The September 23, 2026, digest covers three approvals, all classified as 'Other' (FALLBACK type), with zero NMEs, biosimilars, or label expansions. The mix is dominated by two generic/biosimilar entries (CALCIUM GLUCONATE from CIPLA and CYCLOSPORINE from AUROBINDO PHARMA LTD) and one label expansion for EMPAGLIFLOZIN from RIDHISIDHI, PLLC. No dominant therapeutic area theme emerges, as the drugs target distinct mechanisms (SGLT2 inhibition, electrolyte replacement, immunosuppression). The highest-conviction signal is the bullish label expansion for EMPAGLIFLOZIN, though its commercial materiality is limited by a lack of disclosed peak sales and exclusivity data. The key risk is the absence of high-value NME or breakthrough therapy approvals, indicating a low-catalyst period for small-cap biotech investors.

3 total filings
· daily

Big Pharma Approvals — September 23, 2026

During the period of September 23, 2026, two label expansion approvals were granted, both classified as 'Other' with no NMEs, biosimilars, or standard label expansions. The approvals were for abemaciclib (Verzenio) by Eli Lilly and finerenone (Kerendia) by Bayer, both in the cardiovascular/oncology space, signaling continued lifecycle management in these therapeutic areas. Both approvals carry a bullish signal with moderate strength and materiality, indicating incremental commercial value rather than transformative shifts. The highest-conviction signal is the label expansion for finerenone, which strengthens Bayer's position in chronic kidney disease and heart failure, potentially expanding its addressable patient population. Key watch items include the specific indications added and any competitive responses from other CDK4/6 inhibitors or mineralocorticoid receptor antagonists.

2 total filings
· daily

Orphan Drug Approvals — September 23, 2026

This digest covers a single approval on September 23, 2026, comprising zero NMEs, zero biosimilars, zero label expansions, and one 'Other' approval type. The sole event is a label expansion for LEVACETYLLEUCINE (AQNEURSA) by INTRABIO, classified as a FALLBACK approval with a bullish signal. With no NMEs or biosimilars, the period lacks the high-value catalysts or competitive disruption events that typically drive sector-wide moves. The key signal is INTRABIO's ability to secure a label expansion for an orphan drug, though the lack of disclosed commercial data (peak sales, pricing, market position) limits conviction. The primary risk is the absence of any NME or biosimilar activity, which may indicate a quiet period for pipeline catalysts.

1 total filings
· daily

New Drug Approvals (Original) — September 23, 2026

The September 23, 2026 FDA approval stream was muted, with zero NMEs, zero biosimilars, and zero label expansions, comprising three 'Other' approvals. The period lacked high-value catalysts, with no new molecular entities or biosimilar entrants to drive sector rotation. The lone bullish signal came from RIDHISIDHI, PLLC’s label expansion for EMPAGLIFLOZIN, though the commercial materiality remains NOT_DISCLOSED, limiting conviction. Two neutral biosimilar approvals for CALCIUM GLUCONATE (CIPLA) and CYCLOSPORINE (AUROBINDO PHARMA LTD) reflect routine generic competition in mature markets with no disruptive pricing or market share implications. The key watch item is the absence of NME approvals, which signals a quiet period for pipeline-driven upside and may shift investor focus to late-stage clinical catalysts or upcoming PDUFA dates.

3 total filings
· daily

VA Healthcare & Services Contracts — September 23, 2026

Over this single-day snapshot (September 23, 2026), two civilian VA contracts totaling $581.8 million were awarded, with zero defense exposure. The dominant story is the VA's continued push for IT modernization and healthcare services, anchored by MetGreen Solutions Inc.'s massive $389.5 million firm-fixed-price SDVOSB delivery order for ServiceNow SaaS licenses—a bullish, high-conviction signal for cloud infrastructure spending. OptumServe Health Services, a UnitedHealth Group subsidiary, won a competitive $192.3 million medical evaluation contract, but its short one-year duration and high fixed-price risk temper enthusiasm. Key watch items: MetGreen's execution capacity given its small size relative to the contract, and OptumServe's unspent $112.8 million funding outlay pace.

2 total filings
· daily

New Federal Contractors — September 23, 2026

This digest covers $1.053 billion in federal obligations from four contracts awarded between 2016 and 2025, with only one of four being defense-related (Booz Allen Hamilton's GSA IT award), indicating a civilian-heavy tilt. The dominant theme is IT modernization and healthcare services, with the Department of Veterans Affairs accounting for two large awards totaling $581.8 million. The highest-conviction signal is MetGreen Solutions Inc.'s $389.5 million SDVOSB set-aside for ServiceNow SaaS, which offers multi-year revenue visibility but carries execution risk given the company's small size relative to the contract value. A key risk is OptumServe's $192.3 million one-year fixed-price contract with only $79.5 million outlayed, suggesting potential funding or performance contingencies.

4 total filings
· daily

Significant Contract Modifications ($10M+) — September 23, 2026

The four contract modifications totaling $1.05 billion are overwhelmingly civilian, with only one defense-related award (Booz Allen Hamilton via GSA, $192.6M), signaling continued strength in federal IT modernization and healthcare services rather than defense-specific spending. The dominant theme is civilian agency IT and health services, led by the VA ($581.8M combined to MetGreen and OptumServe) and HHS/BARDA ($278.8M to Regeneron), reflecting sustained investment in cloud-based IT (ServiceNow), biodefense R&D, and medical evaluations. The highest-conviction signal is MetGreen Solutions' $389.5M VA award for ServiceNow SaaS licenses, a bullish multi-year revenue stream with a 7/10 signal strength, though its SDVOSB set-aside status and small size relative to contract value pose execution risks. Key risks include the short duration and high pricing risk of OptumServe's $192.3M VA contract, and potential budget or policy shifts affecting BARDA's biodefense funding. Watch for option exercises on MetGreen and Regeneron contracts, and the outlay rate of OptumServe's remaining $112.8M.

4 total filings
· daily

Contract Deobligations Alert — September 23, 2026

This $1.05 billion digest covers four federal contracts awarded between 2016 and 2025, with only one of four classified as defense-related (Booz Allen Hamilton's $192.6 million GSA Mission IT award), highlighting a pronounced civilian agency tilt led by the Department of Veterans Affairs. MetGreen Solutions Inc. dominates with a $389.5 million SDVOSB set-aside for ServiceNow SaaS licenses—the highest-conviction, highest-materiality signal in the batch, pointing to sustained VA IT modernization spending. A key risk is the $112.8 million un-outlayed balance on OptumServe's $192.3 million VA medical evaluation contract, which raises questions about near-term funding execution under a one-year fixed-price structure with no options. Regeneron's $278.8 million BARDA biodefense contract adds a durable, cost-sharing long-term revenue stream through 2027, reinforcing favorable sector exposure for biodefense and pandemic preparedness. Cross-contract, the VA awarded two of four contracts ($581.8 million combined), signaling high agency concentration risk for contractors heavily reliant on a single civilian buyer.

4 total filings
· daily

Contract Option Exercises — September 23, 2026

The September 23, 2026 contract option exercise stream totals $1.05 billion in obligations, with 3 of 4 awards going to civilian agencies (VA, HHS, GSA) and only one defense-related contract, reflecting a civilian-heavy procurement mix. The dominant theme is IT modernization and healthcare services, led by a $389.5 million VA award to MetGreen Solutions for ServiceNow SaaS licenses—the highest-conviction signal with a 7/10 strength and 8/10 materiality. Regeneron's $278.8 million BARDA contract underscores sustained biodefense investment, while Booz Allen's $192.6 million GSA IT delivery order and OptumServe's $192.3 million VA medical evaluation award highlight stable demand in their respective niches. Key risks include execution capacity for MetGreen given its small-business size, the short duration of OptumServe's contract, and the negative outlayed amount on Booz Allen's award. Watch for option exercises on MetGreen and Regeneron contracts, and monitor VA budget allocations for IT and medical services.

4 total filings
· daily

Federal IT & Cybersecurity Contracts — September 23, 2026

This digest covers two civilian-agency IT contracts totaling $582.1 million, with zero defense exposure, signaling robust demand for cloud-based IT systems and mission-critical IT services from the VA and GSA. The highest-conviction signal is MetGreen Solutions Inc.'s $389.5 million SDVOSB set-aside award for ServiceNow SaaS licenses, which underscores a dual government priority: IT modernization and veteran-owned business support. However, the fixed-price structure and MetGreen's small size relative to the $871.5 million total potential value introduce execution and margin risk. Booz Allen Hamilton's $192.6 million cost-plus award from GSA FEDSIM provides a low-risk, predictable revenue stream, reinforcing its competitive position in federal IT systems development. Key watch items include VA budget allocations for IT modernization and the exercise of MetGreen's contract options through 2027.

2 total filings
· daily

All HHS Contracts — September 23, 2026

This digest covers a single, highly material $278.8 million contract from the Department of Health and Human Services (HHS) awarded to Regeneron Pharmaceuticals. The award is entirely civilian (HHS/BARDA), not defense-related, despite the stream flagging one defense-related record. The dominant theme is sustained U.S. government investment in biodefense and pandemic preparedness, with Regeneron’s monoclonal antibody platform receiving a long-term, cost-sharing commitment. The highest-conviction signal is the strong cash flow visibility from $236.3 million already outlayed against the $278.8 million obligation, indicating execution momentum. A key risk is the cost-sharing structure, which caps profit margins and introduces budget dependency on BARDA’s future appropriations under a new administration.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — September 23, 2026

Over a single day in late September 2026, the federal government obligated $1.053 billion in mega-contracts ($100M+), with only 1 of 4 awards defense-related, signaling a civilian-heavy spending burst. The Department of Veterans Affairs drove the majority ($581.8M across two awards), underscoring a structural shift toward VA IT modernization and medical services. The highest-conviction signal is MetGreen Solutions Inc.'s $389.5M SDVOSB set-aside for ServiceNow licenses, a bullish multi-year IT win that boosts a small contractor but carries execution risk. A key watch item is the $112.8M unfunded portion of OptumServe's VA medical evaluation contract, which could pressure UnitedHealth's outlay pace in fiscal 2027. The digest reveals a bifurcated civilian market: booming IT cloud spend vs. mature healthcare services with thin visibility.

4 total filings
· daily

High-Value Federal Grants ($5M+) — September 23, 2026

This digest covers $1.05 billion in high-value federal obligations from September 2026, with a 1:3 defense-to-civilian split dominated by civilian agencies (VA, HHS, GSA). The highest-conviction signal is a $389.5 million SDVOSB set-aside award to MetGreen Solutions Inc. by the VA for ServiceNow SaaS, highlighting a strong push for cloud IT modernization within veteran healthcare. However, the digest reveals a critical concentration risk: the VA accounts for two of the four awards ($581.8M total), creating outsized exposure to VA budget execution. A key watch item is the execution risk for MetGreen, a small business facing a contract worth nearly 4x its likely annual revenue, and the short, one-year duration of OptumServe's $192.3M medical evaluation contract, which offers no long-term revenue visibility.

4 total filings
· daily

General Federal Contracts — September 23, 2026

This digest covers $1.05 billion in federal contract obligations from September 2016 to September 2026, with a 1:4 defense-to-civilian ratio. The dominant theme is civilian agency IT modernization and healthcare services, led by the Department of Veterans Affairs (VA), which accounts for 55% of total value via two large awards. The highest-conviction signal is MetGreen Solutions Inc.'s $389.5 million ServiceNow SaaS award, a bullish indicator for cloud IT demand and veteran-owned small business set-asides, though its execution capacity is a key risk. A bearish undercurrent exists in the short-duration, fixed-price nature of OptumServe's $192.3 million VA medical evaluation contract, which carries high execution risk and limited revenue visibility beyond one year. Investors should watch VA budget allocations and the exercise of contract options for MetGreen and Regeneron Pharmaceuticals.

4 total filings
· daily

S&P 500 Technology Sector SEC Filings — September 23, 2026

The 15 filings from S&P 500 Technology constituents reveal a concentrated wave of insider stock sales and equity-based compensation activity, predominantly among senior executives at Oracle, Salesforce, and several high-growth tech firms. A notable pattern emerges of C-suite officers (CEOs, CFOs, Presidents) executing large option exercises and subsequent share withholding for taxes, alongside direct open-market sales under 10b5-1 plans. While many transactions are tax-related and not necessarily bearish, the sheer volume and concentration—especially at Oracle (6 filings) and Salesforce (4 filings)—signal a period of significant insider liquidity events. The absence of any open-market buying or bullish insider activity is a key negative sentiment indicator for the sector. No period-over-period financial comparisons, forward-looking guidance, or capital allocation data were present in these filings, limiting the ability to assess fundamental trends. The most material signals are the CFO sales at Datadog and Arista Networks, and the CEO tax-withholding events at Oracle, which collectively suggest management teams are taking profits or managing tax liabilities at current elevated valuations.

15 high priority 15 total filings